Systematic review finds cannabinoids may improve behavioral symptoms and sleep in people with autism
A systematic review of 10 studies found cannabinoids, primarily CBD-rich preparations, appeared to improve problem behaviors, sleep, and hyperactivity in people with autism, while also reducing seizures in those with comorbid epilepsy.
Quick Facts
What This Study Found
Cannabinoids improved some autism-associated symptoms including problem behaviors, sleep problems, and hyperactivity, with limited side effects. They also reduced medication burden and seizure frequency in patients with comorbid epilepsy. Evidence on core ASD symptoms (social communication, repetitive behaviors) remained scarce.
Key Numbers
10 published studies reviewed plus 4 ongoing trials identified. Most studies used CBD-dominant preparations. Side effects were primarily cardiac and metabolic, described as limited.
How They Did This
Systematic review following PRISMA guidelines, searching Web of Knowledge, PsycINFO, and Embase. Ten studies (8 papers, 2 abstracts) were included, plus 4 ongoing trials from ClinicalTrials.gov.
Why This Research Matters
Autism spectrum disorder has limited treatment options, particularly for associated behavioral symptoms. These preliminary findings suggest cannabinoids could address comorbid symptoms and reduce polypharmacy.
The Bigger Picture
While findings are promising for secondary symptoms, the lack of evidence on core ASD symptoms means cannabinoids currently appear more useful as adjunctive treatment for comorbid conditions rather than as a primary autism treatment.
What This Study Doesn't Tell Us
Most included studies were observational with small samples and no control groups. Heterogeneous study designs, cannabis preparations, and outcome measures make comparison difficult.
Questions This Raises
- ?Will the four ongoing RCTs confirm these preliminary findings?
- ?Can cannabinoids address core ASD symptoms or only associated behaviors?
- ?What is the optimal CBD formulation and dose for ASD?
Trust & Context
- Key Stat:
- Cannabinoids improved behavioral symptoms and reduced medication burden
- Evidence Grade:
- Moderate: systematic review methodology, but most included studies were small and observational.
- Study Age:
- Published in 2020 in Brain Sciences.
- Original Title:
- Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies.
- Published In:
- Brain sciences, 10(9) (2020)
- Authors:
- Fusar-Poli, Laura(2), Cavone, Vito, Tinacci, Silvia, Concas, Ilaria, Petralia, Antonino, Signorelli, Maria Salvina, Díaz-Caneja, Covadonga M, Aguglia, Eugenio
- Database ID:
- RTHC-02561
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Can CBD treat autism?
There is no evidence that CBD treats the core features of autism (social communication difficulties, repetitive behaviors). However, preliminary studies suggest it may help with associated symptoms like problem behaviors, sleep difficulties, and hyperactivity.
What about the connection to epilepsy?
About 20-30% of people with ASD also have epilepsy, and the two conditions share some biological mechanisms involving GABA. In studies where patients had both conditions, cannabinoids appeared to reduce seizure frequency, consistent with CBD's established anti-seizure properties.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02561APA
Fusar-Poli, Laura; Cavone, Vito; Tinacci, Silvia; Concas, Ilaria; Petralia, Antonino; Signorelli, Maria Salvina; Díaz-Caneja, Covadonga M; Aguglia, Eugenio. (2020). Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies.. Brain sciences, 10(9). https://doi.org/10.3390/brainsci10090572
MLA
Fusar-Poli, Laura, et al. "Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies.." Brain sciences, 2020. https://doi.org/10.3390/brainsci10090572
RethinkTHC
RethinkTHC Research Database. "Cannabinoids for People with ASD: A Systematic Review of Pub..." RTHC-02561. Retrieved from https://rethinkthc.com/research/fusar-poli-2020-cannabinoids-for-people-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.